In the current study, our results suggest that GEGR treatment induces a decrease in the ability of tumor cell migration through down regulation of the PI3K/AKT signaling pathway as well as the expression of five migration-related proteins in LLC1 cells and LLC1-derived tumors. The gene discussed is AKT1; the disease is neoplasm.